Prostate Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Prostate Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 2 (2005), Issue 9 (September)

1. Preoperative PSA velocity is an independent prognostic factor for relapse after radical prostatectomy.
   J Clin Oncol, 23(25): 6157-62. [Abstract] [Full-text]
2. Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals.
   J Clin Oncol, 23(25): 6139-48. [Abstract] [Full-text]
3. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer.
   J Clin Oncol, 23(25): 6132-8. [Abstract] [Full-text]
4. Combined affinity labelling and mass spectrometry analysis of differential cell surface protein expression in normal and prostate cancer cells.
   Oncogene, 24(38): 5905-13. [Abstract] [Full-text]
5. Methylseleninic acid sensitizes prostate cancer cells to TRAIL-mediated apoptosis.
   Oncogene, 24(38): 5868-77. [Abstract] [Full-text]
6. Distinct cytokine patterns exist in peripheral blood mononuclear cell cultures of patients with prostate cancer.
   Clin Immunol, 117(1): 94-9. [Abstract] [Full-text]
7. cAMP induced modifications of HOX D gene expression in prostate cells allow the identification of a chromosomal area involved in vivo with neuroendocrine differentiation of human advanced prostate cancers.
   J Cell Physiol, 205(2): 202-10. [Abstract] [Full-text]
8. A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer.
   J Natl Cancer Inst, 97(17): 1287-96. [Abstract] [Full-text]
9. Prostate cancer and the Will Rogers phenomenon.
   J Natl Cancer Inst, 97(17): 1248-53. [Abstract] [Full-text]
10. The immunotherapy of prostate and bladder cancer.
    BJU Int, 96(5): 728-35. [Abstract] [Full-text]
11. Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer.
    BJU Int, 96(6): 791-5. [Abstract] [Full-text]
12. A phase II study of nilutamide in men with prostate cancer after the failure of flutamide or bicalutamide therapy.
    BJU Int, 96(6): 787-90. [Abstract] [Full-text]
13. Efficacy of nilutamide as secondary hormonal therapy in androgen-independent prostate cancer.
    BJU Int, 96(6): 783-6. [Abstract] [Full-text]
14. New life after prostate brachytherapy? Considering the fertile female partner of the brachytherapy patient.
    BJU Int, 96(6): 781-2. [Abstract] [Full-text]
15. Is it necessary to separate clinical stage T1c from T2 prostate adenocarcinoma?
    BJU Int, 96(6): 777-80. [Abstract] [Full-text]
16. Does the time from biopsy to surgery affect biochemical recurrence after radical prostatectomy?
    BJU Int, 96(6): 773-6. [Abstract] [Full-text]
17. Individualized screening interval for prostate cancer based on prostate-specific antigen level: results of a prospective, randomized, population-based study.
    Arch Intern Med, 165(16): 1857-61. [Abstract] [Full-text]
18. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial.
    JAMA, 294(10): 1233-9. [Abstract] [Full-text]
19. Apoptosis induction in DU-145 human prostate carcinoma cells.
    Tissue Cell, 37(5): 379-84. [Abstract] [Full-text]
20. Inhibition of the transcription factor Yin Yang 1 activity by S-nitrosation.
    Biochem Biophys Res Commun, 336(2): 692-701. [Abstract] [Full-text]
21. Pim-2 upregulation: biological implications associated with disease progression and perinueral invasion in prostate cancer.
    Prostate, 65(3): 276-86. [Abstract] [Full-text]
22. Possible role of adaptive mutation in resistance to antiandrogen in prostate cancer cells.
    Prostate, 65(3): 268-75. [Abstract] [Full-text]
23. Pilot study of radiofrequency interstitial tumor ablation (RITA) for the treatment of radio-recurrent prostate cancer.
    Prostate, 65(3): 260-7. [Abstract] [Full-text]
24. Mutation screen and association study of EZH2 as a susceptibility gene for aggressive prostate cancer.
    Prostate, 65(3): 252-9. [Abstract] [Full-text]
25. Effect of GnRH analogs on the expression of TrkA and p75 neurotrophin receptors in primary cell cultures from human prostate adenocarcinoma.
    Prostate, 65(3): 195-202. [Abstract] [Full-text]
26. Dual inhibition of the epidermal growth factor and vascular endothelial growth factor phosphorylation for antivascular therapy of human prostate cancer in the prostate of nude mice.
    Prostate, 65(3): 203-15. [Abstract] [Full-text]
27. Assessment of intra-individual variation in prostate-specific antigen levels in a biennial randomized prostate cancer screening program in Sweden.
    Prostate, 65(3): 216-21. [Abstract] [Full-text]
28. Lymphatic vessel density and lymph node metastasis in prostate cancer.
    Prostate, 65(3): 222-30. [Abstract] [Full-text]
29. Patupilone (epothilone B, EPO906) inhibits growth and metastasis of experimental prostate tumors in vivo.
    Prostate, 65(3): 231-40. [Abstract] [Full-text]
30. Effects of econazole on Ca2+ levels in and the growth of human prostate cancer PC3 cells.
    Clin Exp Pharmacol Physiol, 32(9): 735-41. [Abstract] [Full-text]
31. Meta-analysis of soy food and risk of prostate cancer in men.
    Int J Cancer, 117(4): 667-9. [Abstract] [Full-text]
32. Calcitonin increases invasiveness of prostate cancer cells: role for cyclic AMP-dependent protein kinase A in calcitonin action.
    Int J Cancer, 117(4): 551-60. [Abstract] [Full-text]
33. Differential expression of steroid receptors in prostate tissues before and after radiation therapy for prostatic adenocarcinoma.
    Int J Cancer, 117(3): 381-6. [Abstract] [Full-text]
34. Autoantibody signatures in prostate cancer.
    N Engl J Med, 353(12): 1224-35. [Abstract] [Full-text]
35. Effect of dutasteride therapy on Doppler US evaluation of prostate: preliminary results.
    Radiology, 237(1): 197-201. [Abstract] [Full-text]
36. Immunotherapy with allotumour mRNA-transfected dendritic cells in androgen-resistant prostate cancer patients.
    Br J Cancer, 93(7): 749-56. [Abstract] [Full-text]
37. Induction of Th1-type immunity and tumor protection with a prostate-specific antigen DNA vaccine.
    Cancer Immunol Immunother, 54(11): 1082-94. [Abstract] [Full-text]
38. Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy.
    J Clin Oncol, 23(28): 7005-12. [Abstract] [Full-text]
39. Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy.
    J Clin Oncol, 23(28): 6992-8. [Abstract] [Full-text]
40. Laparoscopic radical prostatectomy: conventional and robotic.
    Urology, 66(5): 101-4. [Abstract] [Full-text]
41. Does wide primary perirectal dissection during radical retropubic prostatectomy alter pathologic and biochemical outcomes?
    Urology, 66(5): 95-100. [Abstract] [Full-text]
42. Radical prostatectomy: long-term cancer control and recovery of sexual and urinary function ("trifecta").
    Urology, 66(5): 83-94. [Abstract] [Full-text]
43. Who is the average patient presenting with prostate cancer?
    Urology, 66(5): 76-82. [Abstract] [Full-text]

© 2004-2008 Prostate Cancer Research Today. All Rights Reserved.